There are six disease-modifying agents (DMAs) that have been approved for the treatment of multiple sclerosis (MS). The National MS Society recommends that treatment with one of the medications-interferon beta-1a (Avonex® and Rebif®), interferon beta-1b (Betaseron®), or glatiramer acetate (Copaxone®)-be considered as soon as the diagnosis of MS with a relapsing course or clinically isolated syndrome have been confirmed. Intravenous Mitoxantrone and Tysabri are usually recommended as second line treatment. Recently there have been some changes in the formulation of the disease modifying agents and our goal is to inform our nurses about the changes (please refer to the specific pharmaceuticals web sites for more information).